INmune Bio

Yahoo Finance • 13 days ago

Here are the major earnings after the close Monday

Major earnings expected after the bell on Monday include * Virgin Galactic Holdings (SPCE [https://seekingalpha.com/symbol/SPCE]) * Anadarko Petroleum Corp. (APC [https://seekingalpha.com/symbol/APC]) * Sangamo Therapeutics (SGMO [h... Full story

Yahoo Finance • 14 days ago

INmune Bio FY 2025 Earnings Preview

* INmune Bio (INMB [https://seekingalpha.com/symbol/INMB]) is scheduled to announce FY earnings results on Monday, March 30th, after market close. * The consensus EPS Estimate is -$0.27 [https://seekingalpha.com/symbol/INMB/earnings/es... Full story

Yahoo Finance • 14 days ago

Earnings week ahead: NKE, TLRY, SPCE, BYND, NNDM, CAG, and more

[Nest of Eggs] LindaJoHeilman As the calendar turns from March to April, a holiday-shortened week still delivers a diverse set of earnings with the potential to offer fresh directional cues. Consumer and brand momentum will be in focus w... Full story

Yahoo Finance • 24 days ago

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (N... Full story

Yahoo Finance • 2 months ago

INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB

Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study Boca Raton, FL, Feb. 19, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ... Full story

Yahoo Finance • 4 months ago

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and rese... Full story

Yahoo Finance • 4 months ago

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging d... Full story

Yahoo Finance • 5 months ago

INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference

Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease confe... Full story

Yahoo Finance • 5 months ago

INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update

BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to... Full story

Yahoo Finance • 8 months ago

INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift

Earnings Call Insights: INmune Bio (INMB) Q2 2025 MANAGEMENT VIEW * David J. Moss announced his appointment as Chief Executive Officer following the retirement of co-founder RJ Tesi, stating, "I'm honored to address you today as the ne... Full story

Yahoo Finance • 8 months ago

INmune Bio August 2025 slides: three-platform strategy shows clinical progress

Introduction & Market Context INmune Bio Inc (NASDAQ:INMB) presented its corporate strategy and clinical progress in August 2025, highlighting advances across its three immunomodulatory platforms. The biotech company, which focuses on ha... Full story

Yahoo Finance • 8 months ago

INmune Bio Inc. Announces Second Quarter 2025 Results, Provides Business Update and Announces Management Changes

BOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, to... Full story

Yahoo Finance • 8 months ago

What's going on in today's pre-market session

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT PBM [https://www.chartmill.com/stock... Full story

Yahoo Finance • 8 months ago

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company, today... Full story

Yahoo Finance • 8 months ago

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference

Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will b... Full story

Yahoo Finance • 9 months ago

INmune  slides again as Scotiabank, RJ cut ratings after Alzheimer’s drug miss

Investing.com -- INmune Bio (NASDAQ:INMB) shares fell another 6% to about $2.17 on Tuesday after brokerages downgraded the stock, saying failure of the company’s experimental Alzheimer’s drug XPro in a mid‑stage trial sharply weakens its... Full story

Yahoo Finance • 9 months ago

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on... Full story

Yahoo Finance • 9 months ago

INmune Bio stock downgraded by Raymond James after Alzheimer's trial miss

Investing.com - Raymond James downgraded INmune Bio Inc. (NASDAQ:INMB) from Outperform to Market Perform following disappointing Phase 2 trial results for the company’s XPro therapy in early Alzheimer’s disease. The stock has fallen over... Full story

Yahoo Finance • 9 months ago

INmune Bio fails to meet main goal in Alzheimer's treatment study

[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images Shares of INmune Bio (NASDAQ:INMB [https://seekingalpha.com/symbol/INMB]) dropped on Monday after the company did not achieve the main goal in a mid-stage trial for i... Full story

Yahoo Finance • 9 months ago

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease

In the Phase 2 MINDFuL trial of XPro™ in patients with early Alzheimer’s Disease (AD) with biomarkers of inflammation, the modified intent-to-treat (mITT) population (n=200) did not meet the primary cognitive endpoint (EMACC), however in a... Full story